• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

    2.660 -0.230 (-7.96%)
    Delayed Quote Updated: 4:00 PM EDT, Oct 14, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 180,162
    Open 2.850
    Bid (Size) 2.660 (1,200)
    Ask (Size) 2.820 (400)
    Prev. Close 2.890
    Today's Range 2.660 - 2.889
    52wk Range 2.070 - 16.36
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment
    Via Investor Brand Network
    News headline image
    Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built ↗
    Biotech stocks trade on FDA trial phases. Phase 2 data often builds value, cash runway limits dilution, and Quantum BioPharma just began a phase 2 MS trial. 
    Via MarketBeat
    Topics Artificial Intelligence

    Performance

    52-Week Range 83.7% below 52-week high
    2.660
    2.0752W Low 16.3652W High
    1 Week 17.6% below 1-week high
    2.801W Low 3.231W High

    Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM) traded between $2.07 and $16.36 over the past 52 weeks and last traded at $2.66, 83.7% below its 52-week high. Over the past week it ranged between $2.80 and $3.23.

    Past 12 Months
    -15.4%
    -23.1%
    -23.8%
    -11.9%
    -62.1%
    -82.5%
    1W -$0.48
    1M -$0.80
    3M -$0.83
    6M -$0.36
    YTD -$4.35
    1Y -$12.53

    QNTM was -82.5% over the past year, -11.9% over six months, -62.1% year to date, -15.4% in the last week.

    12 Months vs Market
    QNTM
    -82.5%
    DIA
    +11.9%
    SPY
    +16.1%
    QQQ
    +21.1%
    IWM
    +11.0%

    Over the past 12 months QNTM returned -82.5% versus DIA (Dow) +11.9%, SPY (S&P 500) +16.1%, QQQ (Nasdaq 100) +21.1% and IWM (Russell 2000) +11.0%.

    Volume & Liquidity 0.88× 3-mo avg
    Today 180,162 3-mo avg 205.2K
    1W
    119.7K
    1M
    202.0K
    3M
    205.2K
    6M
    279.0K
    YTD
    279.1K
    1Y
    241.6K

    QNTM most recently traded 180,162 shares against a 3-month average daily volume of 205.2K.

    More News

    Read More
    News headline image
    World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares
    From Quantum BioPharma
    Via GlobeNewswire
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in BioMedWire Editorial on Lucid-MS Phase 2 Trial
    Via Investor Brand Network
    Quantum BioPharma Ltd. (NASDAQ: QNTM) Enlists Thermo Fisher’s Clinical Research Business to Launch Phase 2 Lucid-MS Trial
    Via Investor Brand Network
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial
    Via Investor Brand Network
    News headline image
    Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
    From Quantum BioPharma
    Via GlobeNewswire
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast
    Via Investor Brand Network
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Co-Founder Discusses Lucid-MS Phase 2 Program, unbuzzd(TM) in BioMedWire Podcast
    Via Investor Brand Network
    Quantum BioPharma Ltd. (NASDAQ: QNTM) Receives FDA Green Light to Move Lucid-MS into Phase 2 Testing
    Via Investor Brand Network
    InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Licensee Unbuzzd Wellness Appoints Michael “Zappy” Zapolin CEO
    Via Investor Brand Network
    News headline image
    Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO
    From Quantum BioPharma
    Via GlobeNewswire
    Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
    Via Investor Brand Network
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Announces that Rodman & Renshaw Initiates Coverage with Buy Rating, $8 Price Target
    Via Investor Brand Network
    News headline image
    Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target
    From Quantum BioPharma
    Via GlobeNewswire
    News headline image
    Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
    From Quantum BioPharma
    Via GlobeNewswire
    NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND
    Via Investor Brand Network
    News headline image
    NetworkNewsAudio Announces Audio Press Release (APR) Discussing FDA Clearance for Trial of First-in-Class Treatment Creating ‘Rare Moment’ in MS Research
    From NetworkNewsWire
    Via GlobeNewswire
    News headline image
    Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials
    From Quantum BioPharma Ltd.
    Via GlobeNewswire
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
    Via Investor Brand Network
    Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
    Via Investor Brand Network
    MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance
    Via Investor Brand Network
    BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial
    Via Investor Brand Network
    News headline image
    Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
    From BioMedWire
    Via GlobeNewswire

    Frequently Asked Questions

    Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?
    Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.
    What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?
    Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
    The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market
    What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
    The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 2.660
    When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?
    The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 10/14/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.